2019 Preliminary List of Investors (registered up to August 16th):
Almirall is a leading skin-health focused global pharmaceutical company that partners with healthcare professionals, applying Science to provide medical solutions to patients and future generations. Our efforts are focused on fighting skin health diseases and helping people feel their best. We support healthcare professionals in continuous improvement, bringing our innovative solutions where they are needed.
The company, founded almost 75 years ago and with headquarters in Barcelona, is listed on the Spanish Stock Exchange (ticker: ALM). Almirall has become a key element of value creation to society according to its commitment with its shareholders and its decision to help others by understanding their challenges and using Science to provide solutions for real life. Total revenues in 2018 were 811 million euros. Almirall has more than 1,800 employees.
Alta Life Sciences is a leading multistage venture capital investment firm. Alta LS will invest in companies at all stages of development: from seed financing through commercial growth. Alta LS invests in all areas of life sciences including biotechnology, medical devices, diagnostics, genomics and digital health.
Alta LS is a bridge fund, connecting both sides of the Atlantic, joining the Spanish life sciences ecosystem with the Venture Capital expertise of Silicon Valley.
BeAble Capital is an independent Venture Capital firm specialized in Indutrial High Technology transfer and Seed and Early stages.
Investment on Seed and Early Stage in Industrial High Technologies with the goal to transfer to the society the technologies coming from academic and research institutions, providing support for translating breakthrough discoveries into products thorught start-ups internationally competitive.
Biocrew aims to be a network of private investors promoted by different agents and investors, with the goal of boosting entrepreneurial and investment activity linked to life sciences and technology..
The Centre for the Development of Industrial Technology (CDTI) is a Public Business Entity, answering to the Ministry of Economy and Competitiveness, which fosters the technological development and innovation of Spanish companies. It is the entity that channels the funding and support applications for national and international R&D&i projects of Spanish companies. The CDTI thus seeks to contribute to improving the technological level of the Spanish companies by means of implementing the following activities:
- Financial and economic-technical assessment of R&D projects implemented by companies.
- Managing and fostering Spanish participation in international technological cooperation programmes.
- Fostering international business technology transfer and support services for technological innovation.
- Supporting the setting up and consolidating technological companies.
Clave Mayor is a venture capital firm, focused in tech transfer projects mainly in Spain. We manage currently several funds in investment process with a total volume of more than 30 million euros to invest in different sectors, one of which is Health, counting on not only biotech projects but also and more precisely, Applied Technologies Spinoffs/Startups referred to Medical Devices, mHealth, e-Health…
Our purpose is to invest after the Proof of Concept (TRLs 4-9), in dealflow coming from Universities, Research Centers, or other origins, in a very early stage even taking part in the settlement of the companies (or during the first years) and supporting the startups generating value, not only from a financial or legal perspective but also in fulfilling their strategic goals, thanks to our background investing in Health and also to the involvement of some of our Limited Partners, who are already players in the sector.
Clave Mayor was launched in 2002 in Pamplona (North of Spain) where we have our Headquarters. We currently have also branch offices in Valladolid and Valencia and we have managed during this 15 years more than a 100MM€.
Columbus Venture Partners is a Spanish independent venture capital that brings a unique approach for investing in outstanding early-stage and high growth opportunities in the life science industry of Spain. Our team includes solid and internationally experienced investment professionals with a deep scientific, medical and business development background combined with a proven experience in building and investing in companies to accelerate their commercialization. The combination of industry possibilities and investment experience will provide Limited Partner investors in the Fund a level of professionality and deep expertise that is essential for success in this field.
Demeter is a major player in venture capital and private equity for the energy and ecological transition. We invest from 1 M€ to 30 M€ to support companies at all stages of their development: innovative startups, high growth SMEs and infrastructure projects.
The leading pan-European exchange with global reach and local presence.
Euronext supports companies from local and international blue chips to small and medium enterprises with listing services to meet their specific needs. Issuers in all geographies and from all sectors can grow by raising capital on our regulated markets in Amsterdam, Brussels, Dublin, Lisbon, London, Oslo and Paris, and benefit from exposure to the exchange’s diverse, international client base.
The European Investment Bank is the lending arm of the European Union. We are the biggest multilateral financial institution in the world. The EIF specialises in finance for small businesses and mid-caps. We have more than 60 years’ experience and expertise in project financing.
Exeltis is the result of the natural evolution and sustained growth of the Insud Pharma pharmaceutical business, an integrated health sciences group. It combines the Group’s know-how and experience with the innovative spirit of Exeltis, becoming a global organization with the capacity to discover, develop, produce and market medicinal products and medical devices that can help to improve the quality of life of millions of people worldwide.
Fund+ invests in innovative life sciences companies primarily active in therapeutics, as well as companies developing diagnostics and medical devices.
The companies will be seeking for a series A or B financing and will have already a Proof of Concept (POC).
Fund+ aims at realizing an attractive financial return as well as a societal return. Fund+ wants to contribute in a sustainable way to the improvement of the eco system for biotech companies.
As of today Fund+ has raised 200 Mio euro of financing commitments. The investors are high net worth individuals, family offices and governmental agencies, which all share the same long term vision and societal values of the founders. The intended investment size per company will be between 5 and 15 mio euro spread over different milestones.
GENESIS Ventures will fund projects or start-ups with 50.000 to 100.000 € tickets depending on the identified development needs. The investment period of the vehicle will finish in October 2019.
Our scope is pan European, where we participate together with institutions, research organizations, investors, start-ups and corporations in making good businesses happen. We invest directly in companies through our own fund “Hasten seed fund” and operate different Open Innovation Platforms, such as Innolabs or BioLabs. We help Research Centers on Technology Transfer. And we work for Corporations and bigger Investors as M&A advisors bringing to them the best Ventures.
Hasten Ventures specializes in seed, early stage and pre-series A investments of technology companies, with a special focus in Southern Europe and companies with strong IPRs, particularly in Health Sector.
ILANA Capital is a Special Situations and Alternative Investment Fund that directs financial resources to Life Science and Innovation technologies.
ILANA´s partners have a strong background gained in the best investment banks (Goldman Sachs & JP Morgan) in the most competitive landscapes (NYC & London)
Inveready is one of the leading early-stage venture capital funds in Spain and a pan European hybrid quasi equity investor in small cap quoted companies.
Inveready, through its seven funds, invests both Equity and Venture Debt in technology companies, with high growth potential and innovative business models. Inveready has more than 80 portfolio companies that are leaders in their respective markets. Inveready also invests in quoted continental European companies with hybrid quasi equity instruments through a dedicated fund.
Invivo Capital Partners manages Invivo Ventures, a VC fund that has achieved a first closing of 40M€. It is focused on investing in early-stage companies in the healthcare sector: biotech, medtech, IVD and e-health projects. Our average ticket per company is around 0,5M€ and 2M€ (pre-seed and seed series) with the capacity to further invest through follow-ons in later stages of the best performing portfolio companies depending on the project and financial needs. Geographic focus is mainly Spain but other European companies are considered.
The team also manages Healthequity, SCR. since 2013, a VC fund also focused on the healthcare sector, which has already finished its investment period.
IPF Partners is a leading alternative financing provider focused on the healthcare sector. IPF Partners invests directly in emerging commercial stage pharma/biotech, medtech, diagnostics and IT healthcare companies.
IPF Partners provides customised low- to non-dilutive debt and equity financing to market leading healthcare companies.
The focus is on innovating products at commercial stage with a high potential in attractive markets. Typical deal size ranges from €5-20m+ over a 3- to 6-year duration.
Italfarmaco is a pharmaceutical laboratory born in Milan in 1938 with the purpose of covering the needs of drugs for the health care with maximum efficiency. Our goal is to offer you always the best solution to your needs, therefore we constantly strive to improve the existing medical treatments.
Italfarmaco’s commitment is to offer innovative solutions to current therapeutic options and improve the quality of life of the patients. Focused on certain medical areas such as Gynecology, Dermatology, Respiratory, Bone metabolism and, more recently, Neurology, Oncology, Pediatrics and Psychiatry.
Johnson & Johnson Innovation seeks to positively impact human health through innovation. We do this by helping entrepreneurs realize their dreams of creating healthcare solutions that improve peoples’ lives around the world. We work side-by-side with innovators throughout their journey, providing a robust exchange of ideas and resources to support their success.
Our mission is to create the leading global innovation network to generate transformational healthcare solutions through value-creating partnerships.
OurCrowd was started in 2013, driven by the idea that the business of building startups grows bigger and better when the global ‘crowd’ gains access to VC-level investment opportunities.
Today, OurCrowd is a leading equity crowdfunding platform for investing in global startups, led by serial entrepreneur Jon Medved and run by a team of seasoned investment professionals. Offering unprecedented access to startup investing, individual investors through OurCrowd are fueling innovations that change the way people work, travel, shop, heal, and conduct business. OurCrowd investors participate in these opportunities alongside VCs and institutional co-investors, at the same terms.
Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology.
We have built 16 Vants to date and have raised over $3 billion to pursue our mission. The therapies in development across our family of companies target a wide range of diseases including uterine fibroids, endometriosis, prostate cancer, Parkinson’s disease, diabetes, sickle cell disease, and multiple rare and fatal pediatric conditions.
UNINVEST is a manager of venture capital companies specializing in technology transfer. The management team Uninvest, has over 14 years experience in managing technology transfer funds in Spain.
The track record acquired through management Unirisco and I+D Unifondo, positions us as the team with more experience and track record in investments emerged through processes of technology transfer, having completed the investment cycle in 47 companies and divestment in 35 companies.
With offices across Europe, United States and Asia and with our multi-disciplinary Partner and Advisor teams, Ventac Partners strives to provide its clients superior global services delivered locally.
Covering Biotech, Pharma and Medtech, we offer hands-on experience and skills required to drive innovative technology-based projects from the laboratory to the market.
Over the last 15 years, we have experienced a steadily growing business with industry and academic institutions, we have founded, incorporated and exited several companies together with our partners and investors and consulted on hundreds of different early stage or advanced projects.
Ventac Partners is continuously expanding its international presence and remains committed to generate value to its clients and portfolio company partners and investors.
Ysios Capital is a leading Spanish independent venture capital firm that provides private equity financing to early- and mid-stage human healthcare and life science companies. We target the biotechnology industry, with an exclusive focus on therapeutics.
Founded in 2008, Ysios Capital has € 191,4 million in assets under management through its two funds: Ysios BioFund I (€65 M) and Ysios BioFund II Innvierte (€ 126M).